Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

References

• Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007; 139: 809–819.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376(9747): 1164–1174.
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980.
   PubMed Web of Science ®Google Scholar
• Diehl LF, Karnell LH, Menck HR. The National Cancer data base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999; 86: 2684–2692.
   PubMed Web of Science ®Google Scholar
• Balducci L. ESH-SIOG International Conference on Haematological Malignancies in the Elderly. Expert Rev Hematol 2010; 3(21091143): 675–677.
   PubMedGoogle Scholar
• Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6–14.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49–53.
   PubMed Web of Science ®Google Scholar
• Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27(19075274): 498–503.
   PubMed Web of Science ®Google Scholar
• Foon KA, Mehta D, Lentzsch S, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood 2012; 119: 3184–3185.
   PubMed Web of Science ®Google Scholar
• Chang JE, Kahl BS. Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother 2012; 13: 1495–1505.
   PubMed Web of Science ®Google Scholar
• Reynolds C, Di Bella N, Lyons RM, et al. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs 2012; 30: 1232–1240.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997–1007.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015; 29: 1602–1604.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015; 385(9980): 1873–1883.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079–4088.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–656.
   PubMed Web of Science ®Google Scholar
• Wedding U, Roehrig B, Klippstein A, et al. Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol 2007; 61: 269–276.
   PubMed Web of Science ®Google Scholar
• Rawstron A, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956–964.
   PubMed Web of Science ®Google Scholar
• Machin D, Cheung YB, Parmar MK. Survival curves. survival analysis: a practical approach. 2nd ed. West Sussex, England: Wiley, 23–49.
   Google Scholar
• Mulligan SP, Gill D, Turner P, et al. A randomised dose de-escalation study of oral fludarabine, ± oral cyclophosphamide and intravenous rituximab as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged≥ 65 years: final analysis of response and toxicity [Abstract]. Blood (Suppl) 2014; 124: 3325–3325.
   Google Scholar
• Tam C, Seymour J. Fludarabine. In: Schwab M, editor. Encyclopedia of cancer. Berlin: Springer-Verlag, 2008 1137–1139.
   Google Scholar
• Bouvet E, Borel C, Obéric L, et al. Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia. Haematologica 2013; 98: 65–70.
   PubMed Web of Science ®Google Scholar
• Dartigeas C, Van Den Neste E, Berthou C, et al. Evaluating abbreviated induction with fludarabine, cyclphosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukaemia. Leuk Lymphoma 2015. [Epub ahead of print]. doi: 10.3109/10428194.2015.1063139.
   Web of Science ®Google Scholar
• Gozzetti A, Candi V, Fabbri A, et al. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Leuk Res 2014; 38: 891–895.
   PubMed Web of Science ®Google Scholar
• Mato AR, Foon KA, Feldman T, et al. Reduced‐dose fludarabine, cyclophosphamide, and rituximab (FCR‐Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol 2015;90:487–492.
   PubMed Web of Science ®Google Scholar
• Nikitin E, Kisilichina D, Zakharov O. Randomised comparison of FCR-lite and ClbR (chlorambucil plus rituximab) regimens in elderly patients with chronic lymphocytic leukemia. Hematologica 2013; 98(s1): 473.
   PubMed Web of Science ®Google Scholar
• Smolej L, Brychtova Y, Doubek M, et al. Low-dose FCR is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. updated results of project Q-Lite by Czech CLL Study Group. Blood 2014; 124: 4670.
   Web of Science ®Google Scholar
• Smolej L, Spacek M, Brychtova Y, et al. Low-dose fludarabine and cyclophosphamide combined with rituximab in the treatment of elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): preliminary results of project Q-Lite by Czech CLL Study Group. Blood (Suppl) 2010:2466.
   Google Scholar
• Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117: 3016–3024.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solol-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756–1765.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) shows superior efficacy in comparison to bendamustine and rituximab (BR) in previously untreated and physically fit patients with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). ASH Annual Meeting Abstracts, 2014:19.
   Google Scholar
• Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980–988.
   PubMed Web of Science ®Google Scholar
• Strati P, Keating MJ, O’Brien SM, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 2014; 123: 3727–3732.
   PubMed Web of Science ®Google Scholar
• Pavlovsky A, Fernandez I, Galeano A, et al. Safety and efficacy of abbreviated induction with only 4 cycles of fludarabine (F), cyclophosphamide (C) and rituximab (R) in physically fit patients with chronic lymphocytic leukemia (CLL) who achieve early complete remission (CR) with undetectable minimal residual disease (MDR). Blood 2013; 122: 2886.
   Google Scholar
• Polizzotto MN, Tam CS, Milner A, et al. The influence of increasing age on the deliverability and toxicity of fludarabine‐based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 2006; 107: 773–780.
   PubMed Web of Science ®Google Scholar